{"entity":{"id":"capmatinib","kind":"drug","name":"Capmatinib","aka":["INC280"],"tldr":"Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing.","summary":"Capmatinib is an oral MET inhibitor for metastatic non-small cell lung cancer whose tumours carry a MET exon 14 skipping mutation, present in roughly 3 to 4 percent of lung adenocarcinomas. In the GEOMETRY mono-1 trial it produced responses in most untreated patients and in a smaller share of previously treated ones. The FDA granted accelerated approval in 2020. NICE did not complete its appraisal, so it is not routinely funded in England. Peripheral oedema and nausea are the common side effects.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Capmatinib","links":[{"label":"GEOMETRY mono-1 (NEJM 2020)","url":"https://doi.org/10.1056/NEJMoa2002787"},{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capmatinib"}],"tags":["gap-fill"],"related":["met-ex14"],"cancers":["nsclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met"],"drugs":["tepotinib","crizotinib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":["geometry-mono-1","nct03040973","nct05488314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Tabrecta","modality":"Small-molecule MET tyrosine kinase inhibitor","mechanism":"A selective, ATP-competitive inhibitor of the MET receptor kinase; tumours with MET exon 14 skipping mutations keep the receptor switched on, and blocking it shuts down the growth signal.","approvals":[{"region":"US","year":2020,"indication":"Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"2020-05-06","type":"accelerated-approval","region":"US","note":"Accelerated approval on a surrogate endpoint, with a confirmatory trial required.","indication":"Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test"},{"date":"2022-08-10","type":"conversion","region":"US","note":"Confirmed: the accelerated approval of 2020 converted to traditional approval 2.3 years after it was granted.","indication":"Adult patients with mNSCLC whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test"}]},"route":"/drugs/capmatinib/","neighbours":{"biomarker":[{"id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/"},{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/"}],"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"trial":[{"id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/"},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/"},{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/"},{"id":"nct03784014","kind":"trial","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","route":"/trials/nct03784014/"},{"id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/"}],"paper":[{"id":"paper-wolf-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/"},{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/"}],"term":[{"id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/"}]}}